Vorsitz: Prott, F.-J. (Wiesbaden); Walter, S. (Bonn)
· Best-of-Abstracts-Vortrag: Decision-making processes in multidisciplinary cancer team meetings: a non-participant observational study
Hahlweg, P. (Hamburg)
15:00 - 16:30
London 2 Weitere Themen
ASO
perspektiven eröffnen, Übergänge bewältigen – Beiträge der Sozialen arbeit zur unterstützung von Krebspatienten in umbruchsituationen II
Vorsitz: Dettmers, S. (Kiel); Rösler, M. (Bremen)
· Best-of-Abstracts-Vortrag: Financial toxicity in patients with colorectal and neuroendocrine tumors: impact of a chronic disease on patients' economic situation
Mehlis, K. (Heidelberg)
18:00 - 19:05
Raum A3 Leukämien/Lymphome
multiples myelom
Vorsitz: Blau, I. W. (Berlin); von Lilienfeld-Toal, M. (Jena)
· Best-of-Abstracts-Vortrag: Stability of spinal bone lesions in patients with multiple myeloma after radiotherapy – a retrospective analysis of 130 cases
Lang, K. (Heidelberg)
18:00 - 19:00
Raum M1 Psychoonkologie
PSO
State of the art: lebensqualität
Vorsitz: Kusch, M. (Köln); Wünsch, A. (Freiburg)· Best-of-Abstracts-Vortrag: Effects of an ethics policy on limitations of life-prolonging treatment (EPAL) on DNR orders and transferal to palliative care settings
Mehlis, K. (Heidelberg)
B E S t - o f - a B S t R a c t S - v o R t R ä g E | D o n n E R S t a g 2 2 . 0 2 . 2 0 1 8
8:00 - 9:15
Helsinki 2 Lungentumoren
DG Pneumologie
Strategien in der Krankheitsprogression, (Über-)leben beim nSclc verbessern
Vorsitz: Passlick, B. (Freiburg); Schumann, C. (Kempten)· Best-of-Abstracts-Vortrag: Comprehensive analysis of immune cell infiltrates and cytokine mediators in non-small-cell lung cancer
Stump, J. (München)
8:00 - 9:15
Raum M8 Psychoonkologie
PSO
State of the art: psychosoziale langzeitfolgen der Krebstherapie und versorgungsimplikationen
Vorsitz: Hönig, K. (Ulm); Zimmermann, T. (Hannover)
· Best-of-Abstracts-Vortrag: A randomized clinical trial of coping support intervention for parents of adolescent and young adults (AYA) with hematological malignancies
Köhler, M. (Magdeburg)
8:00 - 9:15
London 2 Translationale Onkologie
IAG-KHT/AHMO/AIO/ARO
Kopf-hals-tumoren – klinische Bedeutung molekularer Subgruppen
Vorsitz: Balermpas, P. (Frankfurt/M.); Reichert, T. E. (Regensburg)· Best-of-Abstracts-Vortrag: P4HA1: a single-gene surrogate of hypoxia signatures in oral squamous cell carcinoma patients
· Best-of-Abstracts-Vortrag: Durvalumab for recurrent/
metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): preliminary results from a single-arm, phase-2-study
Kappler, M. (Halle/S.)
Ochsenreither, S. (Berlin)
8:00 - 9:15
Raum M1 Urogenitale Tumorene
GTCSG
projekte der german-speaking testicular cancer Study group (gtcSg)
Vorsitz: Oing, C. (Hamburg); Souchon, R. (Berlin)· Best-of-Abstracts-Vortrag: Phase-II-study of sequential high-dose-chemotherapy with Paclitaxel, Ifosfamide, Carboplatin, Etoposide (P-ICE) in patients with relapsed or refractory germ cell tumors (GCT)
Cygon, F. (Halle/S.)
3 3 . D E u t S c h E R K R E B S K o n g R E S S 2 1 . – 2 4 . F e b r u a r 2 0 1 8 # D K K 2 0 1 8
206 * Die Zusage lag bei Redaktionsschluss noch nicht vor. 207
B E S t - o f - a B S t R a c t S - v o R t R ä g E | f R E I t a g 2 3 . 0 2 . 2 0 1 8
9:30 - 11:00
Raum A2 Gastrointestinale Tumoren
AIO
State of the art: Internistisch-onkologischer therapiealgorithmus im zeitalter der präzisionsmedizin bei gastroösophagealen tumoren
Vorsitz: Al-Batran, S.-E. (Frankfurt/M.); Weichert, W. (München)
· Best-of-Abstracts-Vortrag: High lymphocyte infiltration as a positive prognostic marker in adenocarcinomas of the esophageal-gastral junction and stomach (AEG/S)
Berndt, M. (Berlin)
9:30 - 11:00
New York 1 Translationale Onkologie
AIO
Innovative ansätze beim pankreaskarzinom
Vorsitz: N. N.; Zender, L. (Tübingen)· Best-of-Abstracts-Vortrag: Differentiation of pancreatic cancer from chronic pancreatitis with a novel plasma- based targeted LC-MS/MS assay
Mayerle, J. (München)
9:35 - 11:05
Raum A5 Leukämien/Lymphome
plenar: lymphome
Vorsitz: Schmitt, C. A. (Berlin); Stilgenbauer, S. (Ulm)
· Best-of-Abstracts-Vortrag: Multicenter prospective international registry for secondary CNS involvement in malignant lymphoma
May, L. (Berlin)
15:00 - 16:30
Raum A3 Mammakarzinom
AGO
State of the art: vermeidung von Übertherapie beim mammakarzinom – Don'ts und Dos der ago mamma
Vorsitz: Dall, P. (Lüneburg); Loibl, S. (Neu-Isenburg)
· Best-of-Abstracts-Vortrag: Health care of breast cancer
patients with disabilties Groß, S. (Köln)
15:00 - 16:30
London 3 Onkologische Pflege
KOK
Symptommanagement
Vorsitz: Hellberg-Naegele, M. (Freiburg); Knötgen, G. (Aurich)
· Best-of-Abstracts-Vortrag: Developing a short form of the German Barriers Questionnaire-II, to measure patient-related barriers to cancer pain management
· Best-of-Abstracts-Vortrag: Evaluation of antiemetic practices for prevention of chemotherapy induced nausea and vomiting (CINV): results of a European oncology nurse survey
Koller, A. (Wien)
Jahn, P. (Halle/S.)
15:00 - 16:30
Helsinki 1 Supportivmedizin
ASORS/DEGRO/DGHO/KOK
State of the art: neue Standards in der Supportivtherapie – S3-leitlinie Supportivtherapie
Vorsitz: Feyer, P. (Berlin); Jordan, K. (Heidelberg)
· Best-of-Abstracts-Vortrag: Aktuelle Patienteninformationen über orale Nebenwirkungen bei Radio-Chemotherapie (deutsche Version der "Fact Sheets" der Oral Care Study Groupt ISOO/MASCC 2016)
Beck-Mannagetta, J. (Salzburg)
15:00 - 16:30
Paris 1 Versorgungsforschung/Qualität
CCC-Netzwerk
aktuelles aus der arbeit des netzwerks der von der Deutschen Krebshilfe geförderten onkologischen Spitzenzentren (ccc-netzwerk)
Vorsitz: Heinemann, V. (München); Nettekoven, G. (Bonn)
· Best-of-Abstracts-Vortrag: Impact of a central coordination service for standard operating procedures (SOPs) – Evalua- tion of a national cooperation of oncological centers of excellence of the German Cancer Aid
Bischoff, M. (Freiburg)
15:00 - 16:30
Paris 2 Weitere Themen
AIO Young Medical Oncologists/Young DEGRO
zukunft der onkologie in Deutschland – gestaltungsmöglichkeiten für junge onkologen
Vorsitz: Bozorgmehr, F. (Heidelberg); Ebert, N. (Dresden)
· Best-of-Abstracts-Vortrag: Student's perception of
radiation and its effects Gneist, N. (Dresden)
3 3 . D E u t S c h E R K R E B S K o n g R E S S 2 1 . – 2 4 . F e b r u a r 2 0 1 8 # D K K 2 0 1 8
208 209
18:00 - 19:00
Paris 2 Mammakarzinom
Best-of-abstracts-vorträge: mammakarzinom
Vorsitz: N. N.; N. N.· Best-of-Abstracts-Vortrag: Impact of MammaPrint and BluePrint on early breast cancer treatment decisions: WSG PRIMe study results
· Best-of-Abstracts-Vortrag: Combination of conventional prognostic factors and molecular subtypes for selecting the timing of systemic therapy in early operable breast cancer
· Best-of-Abstracts-Vortrag: Screening-relevant age treshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology
· Best-of-Abstracts-Vortrag: MONARCH 2: Abemaciclib in combination with Fulvestrant in patients (pts) with refractory hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 negative HER2- advanced breast cancer (ABC) who progressed on endocrine therapy (ET)
· Best-of-Abstracts-Vortrag: MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer
· Best-of-Abstracts-Vortrag: Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: results from the phase-III-Sucess-A-study
· Best-of-Abstracts-Vortrag: Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?
Würstlein, R. (München)
Jackisch, C. (Offenbach)
Inwald, E. (Regensburg)
Grischke, E. M. (Tübingen)
Huober, J. (Ulm)
Friedl, T. W. (Ulm)
Heil, J. (Heidelberg)
B E S t - o f - a B S t R a c t S - v o R t R ä g E |
f R E I t a g 2 3 . 0 2 . 2 0 1 8 B E S t - o f - a B S t R a c t S - v o R t R ä g E |
S a m S t a g 2 4 . 0 2 . 2 0 1 8
9:15 - 10:30
New York 1 Lungentumoren
AIO
zielgerichtete therapien
Vorsitz: Serke, M. (Hemer); Wolf, M. (Kassel)
· Best-of-Abstracts-Vortrag: The CD-Inhibitor Vildagliptin suppresses lung cancer via surfactant-mediated activation of macrophages and NK cells in mice
Jungraithmayr, W.
(Neuruppin)
9:35 - 11:05
Helsinki 2 Kopf-Hals-Tumoren
IAG-KHT/AHMO/AIO/ARO
plenar: neue Standards in der first- und Second-line-therapie beim R/m hnScc?
Vorsitz: Grünwald, V. (Hannover); N. N.
· Best-of-Abstracts-Vortrag: HANNA: a national, prospective, non-interventional study of Nivolumab (Nivo) in patients (pts) with squamous cell carcinoma of the head and neck (SCCHN) progressing on or after platinum-based therapy
Dietz, A. (Leipzig)
9:35 - 11:05
London 3 Psychoonkologie
PSO
plenar: Kommunikation in der palliativen versorgung
Vorsitz: Hönig, K. (Ulm); Vehling, S. (Hamburg)· Best-of-Abstracts-Vortrag: Preferences of patients with advanced cancer in end-of-life decision-making (EPAL-Study)
Jaeger, E. (München)
10:45 - 12:15
New York 2 Gynäkologische Tumoren
DKFBE
Sektorenübergreifende zusammenarbeit bei der Betreuung von Risikofamilien für Brust- und Eierstockkrebs
Vorsitz: du Bois, A. (Essen); Schmutzler, R. (Köln)
· Best-of-Abstracts-Vortrag: Germline loss-of-function variants in BARD1 are associated with familial breast cancer
· Best-of-Abstracts-Vortrag: BRIP1 – a risk gene for breast cancer?
Weber-Lassalle, K. (Köln)
Weber-Lassalle, N. (Köln)
* Die Zusage lag bei Redaktionsschluss noch nicht vor.
3 3 . D E u t S c h E R K R E B S K o n g R E S S 2 1 . – 2 4 . F e b r u a r 2 0 1 8 # D K K 2 0 1 8
210 211
10:45 - 12:15
New York 1 Lungentumoren
AIO
neue praxisrelevante Studienergebnisse
Vorsitz: Dickgreber, N. (Rheine); Wolf, M. (Kassel)· Best-of-Abstracts-Vortrag: Impact of Atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: results from the randomized Ph-III-OAK-study
Serke, M. (Hemer)
10:45 - 12:15
New York 3 Onkologische Pflege
KOK
fachliche führung und neue Rollen
Vorsitz: Hellberg-Naegele, M. (Freiburg); Jahn, P. (Halle/S.)
· Best-of-Abstracts-Vortrag: Zwei Jahre onkologischer Pflege-Konsildienst an der Uniklinik Köln – ein Resümee
· Best-of-Abstracts-Vortrag: Adhärenzsteigerung onkologischer PatientInnen mit oralen antineoplastischen Medikamenten durch die pflegerischen Interventionen der PatientInnen- und Mitarbeitendenedukation
Schneider, E. (Köln) Naumann, I. (Esslingen)
10:45 - 12:15
Raum M8 Weitere Themen
State of the art: Seltene tumorerkrankungen
Vorsitz: Debatin, K.-M. (Ulm); Schuler, M. (Essen)· Best-of-Abstracts-Vortrag: NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous hematological response
Schönland, S. (Heidelberg)
12:45 - 14:00
London 2 Weitere Themen
DGHO/GPOH
Junge Erwachsene mit Krebs
Vorsitz: Eggert, A. (Berlin); Hilgendorf, I. (Jena)· Best-of-Abstracts-Vortrag: Schattenkinder in der Kinderonkologie – welche Unterstützungsmöglichkeiten kann das stationäre Setting bieten?!
Dittmer, M. C. (Mainz)
13:00 - 14:00
New York 3 Hauttumoren
ADO
Immunescape-mechanismen bei checkpoint-Inhibition beim melanom
Vorsitz: Grabbe, S. (Mainz); Mougiakakos, D. (Erlangen)· Best-of-Abstracts-Vortrag: Treat2plus: a comprehensive NGS-based personalized medicine pilot study for the treatment of metastatic melanoma
Yaspo, M.-L. (Berlin)
13:00 - 14:00
Raum M2-3 Rehabilitation
ASORS/PSO
onko-Reha ist auch cancer Survivorship
Vorsitz: Dauelsberg, T. (Nordrach); Steimann, M. (Boltenhagen)
· Best-of-Abstracts-Vortrag: Development and evaluation of a cancer-related fatigue management program for the oncological rehabilitation: a pilot-study
Kähnert, H. (Bad Salzuflen)
13:00 - 14:05
Paris 1 Translationale Onkologie
AIO
Stratifizierung der therapie des KRK – wodurch?
Vorsitz: Kirchner, T. (München); Köhne, C.-H. (Oldenburg)
· Best-of-Abstracts-Vortrag: Recurrence risk prediction by MACC1 expression stratifies stage II colon cancer patients with proficient mismatch repair status: the BIOGRID studies
Stein, U. (Berlin)
13:00 - 14:05
Raum M1 Versorgungsforschung/Qualität
DGHO/BNHO
versorgungsforschung in der onkologie – was kann sie (nicht) leisten?
Vorsitz: Baumann, W. (Köln); Lüftner, D. (Berlin)
· Best-of-Abstracts-Vortrag: "Cancer in Germany" 2017 –
nationwide cancer statistics Wolf, U. (Berlin)
B E S t - o f - a B S t R a c t S - v o R t R ä g E |
S a m S t a g 2 4 . 0 2 . 2 0 1 8
3 3 . D E u t S c h E R K R E B S K o n g R E S S 2 1 . – 2 4 . F e b r u a r 2 0 1 8 # D K K 2 0 1 8 212
14:15 - 15:15
Helsinki 1 Gynäkologische Tumoren
Best-of-abstracts-vorträge: gynäkologische tumoren und mammakarzinom
Vorsitz: N. N.; N. N.· Best-of-Abstracts-Vortrag: IORT boost in breast cancer patients – long term results up to 15 years
· Best-of-Abstracts-Vortrag: Results from the PASSOS heart study
· Best-of-Abstracts-Vortrag: Phase-III-randomized- controlled-study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer – AGO Desktop III / ENGOT OV20
· Best-of-Abstracts-Vortrag: The prognostic value of tumor residuals (TR) indicated by surgeon (SA), by radiology (RA), or an integrated approach (IA) by surgeons' assessment and pre-chemotherapy CT-scan in patients with advanced ovarian cancer: an exploratory analysis of the AGO led
· Best-of-Abstracts-Vortrag: Lion-lymphadenectomy in ovarian neoplasms. A prospective randomized ago study group led gynecologyc cancer intergroup trial
· Best-of-Abstracts-Vortrag: Analysis of FOXL2 – mutation status in 41 cases of ovarian sertoli – leydig cell tumors (SLCT)
Sperk, E. (Mannheim) Bartkowiak, D. (Ulm) Hillemanns, P. (Hannover)
Heitz, F. (Essen)
Belau, A. (Stralsund)
Keul, J. (Tübingen)
14:15 - 15:20
London 3 Palliativmedizin
DG Palliativmedizin
aktuelle palliativmedizinische problemfelder in der onkologie
Vorsitz: Gerlach, C. (Mainz); Maier, B.-O. (Wiesbaden)· Best-of-Abstracts-Vortrag: Symptoms and palliative care needs of cancer patients at diagnosis of incurability – a pospective longitudinal multicenter cohort study of the Arbeitsgemeinschaft Palliativmedizin (APM)
Vogt, J. (Leipzig)
B E S t - o f - a B S t R a c t S - v o R t R ä g E |
S a m S t a g 2 4 . 0 2 . 2 0 1 8
Register front
Register back
215
p o S t E R B E g E h u n g E n
m I t t w o c h , 2 1 . 0 2 . 2 0 1 8 | 1 6 : 3 0 - 1 8 : 0 0 u h R
posterbegehung: Breast cancer
Moderator: N. N.Control of VEGF expression in breast cancer cells by interleukin-1 and curcumin,
Nass, N. (Magdeburg) ID 92
A randomized, double-blinded pivotal study of tucatinib (ONT-380) vs. placebo in combination with capecitabine and trastuzumab in patients with pretreated HER2-pos.
unresectable locally advanced or metastatic breast cancer: HER2CLIMB, Müller, V. (Hamburg) ID 107
Improvement of bimanual coordination and physical performance after breast cancer
therapy – Results of a specialized rehabilitation program, Heydenreich, M. (Bad Elster) ID 108 RIBANNA – A non-inteventional study (NIS) for postmenopausal women with HR-positive,
HER2-negative locally advanced or metastatic breast cancer to evaluate the real world effectiveness of treatment algorithms beginning with Ribociclib in combination with an aromatase inhibitor (AI), or with endocrine therapy or chemotherapy as first line treatment, Wöckel, A. (Würzburg)
ID 193
Evaluation of the effects of sensorimotor exercises on physical and psychological parameters
in patients with breast cancer, Vollmers, P. L. (Kiel) ID 199
Targeted intraoperative radiotherapy (TARGIT) during breast conserving surgery for early breast cancer in patients after breast augmentation with implants – a case series,
Kolberg, H.-C. (Bottrop)
ID 200
Re-excision rates in breast-conserving surgery for invasive breast cancer after neoadjuvant chemotherapy with and without the use of a radiopaque tissue Transfer and X-ray System, Kolberg, H.-C. (Bottrop)
ID 203
Evaluation of an expert guided integrative therapy concept in patients with breast or
gynecological cancer during systemic therapy, Paepke, D. (München) ID 227 ER stress plays an important role in G-protein-coupled estrogen receptor (GPER)-specific
agonist G1-induced MCF-7 breast cancer cell death, Vo, D.-K. (Magdeburg) ID 238 Selective interaction of triple-negative breast cancer cells with netrin-4 mediated by CD 146
receptor, Burow, H. (Tübingen) ID 278
Diagnostic potential of microRNAs expression profiles in serum and urine of breast and
gynecological cancer patients, Ritter, A. (Freiburg) ID 374
DETECT III and IV – Individualized CTC-based therapy of metastatic breast cancer,
Romashova, T. (Ulm) ID 448
posterbegehung: cancer prevention
Moderator: N. N.Demand for skin cancer prevention in preschools, Herrmann, S. (Dresden) ID 351 Skin cancer prevention starts early in life – the 'SonnenschutzClown' preschool program,
Seidel, N. (Dresden) ID 352
Developing healthy lifestyle habits – successful programs from primary prevention to cancer
survivorship, Stölzel, F. (Dresden) ID 353
Skin cancer screening in Germany: Evaluation of the training program in 2016,
Fengler, S. (Buxtehude) ID 354
Psychological and medical need for assistance in women with increased risk for hereditary breast- and ovarian cancer – A qualitative analysis, Fischer, J. (Hannover) ID 416 Course of High Grade Cervical Intraepithelial Neoplasia diagnosed during Pregnancy,
Grimm, D. (Hamburg) ID 717
Use of Routine Health Care Data: Aspects of Cancer Care in Cervical Cancer Patients in Lower
Saxony between 2010–2015, Tiews, S. (Dortmund) ID 752
3 3 . D E u t S c h E R K R E B S K o n g R E S S 2 1 . – 2 4 . F e b r u a r 2 0 1 8 # D K K 2 0 1 8
216 217
Evaluation of prophylactic mastectomy and breast reconstruction in female BRCA1/2
mutation carriers, Herold, N. (Köln) ID 774
Primary skin cancer prevention – target group: children and young people, Bunde, H. (Hamburg) ID 820 Skin cancer prevention training in elementary schools: Increasing the awareness towards
UV-radiation, Grosskopf-Kroiher, D. (Köln) ID 927